Investment Banking
Private Placement Activity and M&A and Strategic Collaborations
January 04, 2024
Please contact Daniel at [email protected] to request a copy of Oppenheimer's 2023 Year-in-Review and 2024 Outlook for Private Placement Activity and M&A and Strategic Collaborations.
Oppenheimer's 2023 Year-in-Review and 2024 Outlook for Private Placement Activity and M&A and Strategic Collaborations cover the following topics:
- Biotech VC funding environment (including insider vs new investor participation and extension rounds)
- Top therapeutic areas and treatment modalities that attract VC dollars
- Active VC investors and VC fundraising levels
- Valuation dynamics for private biotech companies (including step ups)
- IPO and reverse merger analysis
- FDA approval statistics
- General M&A and BD environment for biopharma companies
- M&A premiums and BD upfronts/milestones broken out by development stage, therapeutic area, and treatment modality
These reports are part of our leadership role in the biopharma sector. We hope to provide you with broader healthcare perspectives and actionable insights. Consider us a partner, trusted advisor, and extension of your team - with The Power of Oppenheimer Thinking.
Please reach out to Michael Margolis, R.Ph. ([email protected]), Daniel Parisotto, PhD ([email protected]), Zelyn Kwok ([email protected]), or Robert Lewis ([email protected]) directly to request a copy.
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Co-Head of Healthcare, Head of Healthcare Life Sciences
Name:
DISCLOSURES
This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
2023 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 6195473.1